Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	103.78	53.51	18.26	9.33	18.15
Revenue Growth (YoY)	93.95%	193.10%	95.67%	-48.59%	357.56%
Gross Profit	103.78	53.51	18.26	9.33	18.15
Selling, General & Admin	25.55	36.48	41.7	21.44	15.59
Research & Development	51.44	47.59	64.53	67	65.78
Other Operating Expenses	5.31	11.63	0	0	0
Operating Expenses	82.3	95.71	106.23	88.44	81.36
Operating Income	21.48	-42.2	-87.97	-79.11	-63.22
Interest Expense / Income	0	2.61	1.94	0	0
Other Expense / Income	-3.92	1.61	-0.16	-0.83	-2.29
Pretax Income	25.4	-46.42	-89.76	-78.28	-60.93
Income Tax	2.6	0	0	0	0
Net Income	22.81	-46.42	-89.76	-78.28	-60.93
Shares Outstanding (Basic)	53	38	31	22	18
Shares Outstanding (Diluted)	53	38	31	22	18
Shares Change	40.98%	21.65%	38.01%	23.27%	13.49%
EPS (Basic)	0.43	-1.23	-2.91	-3.52	-3.35
EPS (Diluted)	0.43	-1.23	-2.91	-3.52	-3.35
Free Cash Flow	-33	-7.73	-64.35	-85.87	-50.33
Free Cash Flow Per Share	-0.63	-0.21	-2.08	-3.84	-2.77
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	20.70%	-78.86%	-481.87%	-847.94%	-348.36%
Profit Margin	21.98%	-86.74%	-491.65%	-839.01%	-335.73%
Free Cash Flow Margin	-31.79%	-14.45%	-352.47%	-920.39%	-277.37%
Effective Tax Rate	10.23%	-	-	-	-
EBITDA	25.77	-42.94	-87.17	-77.52	-60.18
EBITDA Margin	24.83%	-80.25%	-477.49%	-830.86%	-331.60%
Depreciation & Amortization	0.37	0.87	0.65	0.76	0.75
EBIT	25.4	-43.81	-87.82	-78.28	-60.93
EBIT Margin	24.48%	-81.87%	-481.03%	-839.01%	-335.73%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).